1. Home
  2. AGPU vs MDXH Comparison

AGPU vs MDXH Comparison

Compare AGPU & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGPU

Axe Compute Inc. Common Stock

N/A

Current Price

$7.07

Market Cap

36.8M

Sector

N/A

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.55

Market Cap

41.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGPU
MDXH
Founded
2002
2003
Country
United States
Belgium
Employees
14
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
36.8M
41.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AGPU
MDXH
Price
$7.07
$0.55
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
354.8K
730.8K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12,476.23
$30.78
Revenue Next Year
$55.17
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.51
52 Week High
$10.86
$5.33

Technical Indicators

Market Signals
Indicator
AGPU
MDXH
Relative Strength Index (RSI) 53.27 20.90
Support Level $3.66 $0.51
Resistance Level $8.81 $3.79
Average True Range (ATR) 1.03 0.07
MACD -0.13 0.05
Stochastic Oscillator 39.35 12.62

Price Performance

Historical Comparison
AGPU
MDXH

About AGPU Axe Compute Inc. Common Stock

Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: